Svetlana Shulga-Morskaya
Overview
Explore the profile of Svetlana Shulga-Morskaya including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
772
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Subramanian M, McIninch J, Zlatev I, Schlegel M, Kaittanis C, Nguyen T, et al.
Nat Commun
. 2023 Apr;
14(1):1970.
PMID: 37031257
Adeno-associated virus (AAV)-based gene therapy could be facilitated by the development of molecular switches to control the magnitude and timing of expression of therapeutic transgenes. RNA interference (RNAi)-based approaches hold...
2.
Schlegel M, Janas M, Jiang Y, Barry J, Davis W, Agarwal S, et al.
Nucleic Acids Res
. 2022 Jun;
50(12):6656-6670.
PMID: 35736224
Preclinical mechanistic studies have pointed towards RNA interference-mediated off-target effects as a major driver of hepatotoxicity for GalNAc-siRNA conjugates. Here, we demonstrate that a single glycol nucleic acid or 2'-5'-RNA...
3.
Brown C, Gupta S, Qin J, Racie T, He G, Lentini S, et al.
Nucleic Acids Res
. 2020 Aug;
48(21):11827-11844.
PMID: 32808038
One hallmark of trivalent N-acetylgalactosamine (GalNAc)-conjugated siRNAs is the remarkable durability of silencing that can persist for months in preclinical species and humans. Here, we investigated the underlying biology supporting...
4.
Haase N, Foster D, Cunningham M, Bercher J, Nguyen T, Shulga-Morskaya S, et al.
J Clin Invest
. 2020 Apr;
130(6):2928-2942.
PMID: 32338644
No abstract available.
5.
Zlatev I, Castoreno A, Brown C, Qin J, Waldron S, Schlegel M, et al.
Nat Biotechnol
. 2018 May;
36(6):509-511.
PMID: 29786096
We report rapid, potent reversal of GalNAc-siRNA-mediated RNA interference (RNAi) activity in vivo with short, synthetic, high-affinity oligonucleotides complementary to the siRNA guide strand. We found that 9-mers with five...
6.
Janas M, Schlegel M, Harbison C, Yilmaz V, Jiang Y, Parmar R, et al.
Nat Commun
. 2018 Feb;
9(1):723.
PMID: 29459660
Small interfering RNAs (siRNAs) conjugated to a trivalent N-acetylgalactosamine (GalNAc) ligand are being evaluated in investigational clinical studies for a variety of indications. The typical development candidate selection process includes...
7.
Willoughby J, Chan A, Sehgal A, Butler J, Nair J, Racie T, et al.
Mol Ther
. 2017 Oct;
26(1):105-114.
PMID: 28988716
The hepatocyte-specific asialoglycoprotein receptor (ASGPR) is an ideal candidate for targeted drug delivery to the liver due to its high capacity for substrate clearance from circulation together with its well-conserved...
8.
Rajeev K, Nair J, Jayaraman M, Charisse K, Taneja N, OShea J, et al.
Chembiochem
. 2015 Mar;
16(6):903-8.
PMID: 25786782
We recently demonstrated that siRNAs conjugated to triantennary N-acetylgalactosamine (GalNAc) induce robust RNAi-mediated gene silencing in the liver, owing to uptake mediated by the asialoglycoprotein receptor (ASGPR). Novel monovalent GalNAc...
9.
FitzGerald K, Frank-Kamenetsky M, Shulga-Morskaya S, Liebow A, Bettencourt B, Sutherland J, et al.
Lancet
. 2013 Oct;
383(9911):60-68.
PMID: 24094767
Background: Proprotein convertase subtilisin/kexin type 9 (PCSK9) binds to LDL receptors, leading to their degradation. Genetics studies have shown that loss-of-function mutations in PCSK9 result in reduced plasma LDL cholesterol...
10.
Nguyen D, Chen S, Lu J, Goldberg M, Kim P, Sprague A, et al.
Mol Ther
. 2009 Jul;
17(9):1555-62.
PMID: 19584813
RNA interference (RNAi) has generated significant interest as a strategy to suppress viral infection, but in some cases antiviral activity of unmodified short-interfering RNA (siRNA) has been attributed to activation...